The BLUE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLUE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BLUE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BLUE Detailed Price Forecast - CNN Money||View BLUE Detailed Summary - Google Finance|
|View BLUE Detailed Summary - Yahoo! Finance||View BLUE Stock Research & Analysis - Zacks.com|
|View BLUE Trends & Analysis - Trade-Ideas||View BLUE Major Holders - Barrons|
|View BLUE Call Transcripts - NASDAQ||View BLUE Breaking News & Analysis - Seeking Alpha|
|View BLUE Annual Report - CompanySpotlight.com||View BLUE OTC Short Report - OTCShortReport.com|
|View BLUE Fundamentals - TradeKing||View BLUE SEC Filings - Bar Chart|
|View Historical Prices for BLUE - The WSJ||View Performance/Total Return for BLUE - Morningstar|
|View the Analyst Estimates for BLUE - MarketWatch||View the Earnings History for BLUE - CNBC|
|View the BLUE Earnings - StockMarketWatch||View BLUE Buy or Sell Recommendations - MacroAxis|
|View the BLUE Bullish Patterns - American Bulls||View BLUE Short Pain Metrics - ShortPainBot.com|
|View BLUE Stock Mentions - StockTwits||View BLUE Stock Mentions - PennyStockTweets|
|View BLUE Stock Mentions - Twitter||View BLUE Investment Forum News - Investor Hub|
|View BLUE Stock Mentions - Yahoo! Message Board||View BLUE Stock Mentions - Seeking Alpha|
|View Insider Transactions for BLUE - SECform4.com||View Insider Transactions for BLUE - Insider Cow|
|View BLUE Major Holdings Summary - CNBC||View Insider Disclosure for BLUE - OTC Markets|
|View Insider Transactions for BLUE - Yahoo! Finance||View Institutional Holdings for BLUE - NASDAQ|
|View BLUE Stock Insight & Charts - FinViz.com||View BLUE Investment Charts - StockCharts.com|
|View BLUE Stock Overview & Charts - BarChart||View BLUE User Generated Charts - Trading View|
Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
Posted on Friday September 14, 2018
Cellular cancer therapies are a tough sell that could get a lot tougher.
Analyzing Regenxbio’s Valuation Metrics
Posted on Thursday September 13, 2018
Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.
Bluebird Bio Stock May Have Upside of at Least 60 Percent
Posted on Wednesday September 12, 2018
Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?
56% of Analysts Recommend a ‘Buy’ for Editas Medicine
Posted on Monday September 10, 2018
In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.